MarginsXMarginsX
Home › Markets › Health Care › SPRY

ARS Pharmaceuticals Inc. (SPRY)

SPRY trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$3.59
-7.71% on the day
Market cap
$360.9M
Small cap
Revenue · 2025
$84.3M
-5.5% on 2024
Net income · 2025
-$171.3M
-203.3% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1671858/000119312526097478/0001193125-26-097478-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerSPRY on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2020
SEC CIK0001671858
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$84.3M
Net income-$171.3M
Operating income-$179.4M
Net margin-203.3%
Operating margin-212.9%
Revenue growth-5.5%
Cash$41.3M
Total assets$327.7M
P/E (computed)Net income was not positive
P/S (computed)4.3×

Warning signs

Cash runway
1.7 months
$25.6M cash at September 30, 2026
Share count, 1 year
+1.7%
2025-11-06 to 2026-11-03 · +4.7% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
-$1.9M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$25.6M cash; operating cash flow -$45.8M a quarter.Report 2026-09-30
Shares outstanding100,528,400 (2026-11-03); 98,848,611 a year earlier; 95,997,252 three years earlier.Cover page 2026-11-03
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, San Diego, California, United StatesPCAOB Form AP 2026-03-18
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $1.9M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$37.7M-$35.6M-$33.7M$25.6M$121.8M$122.1M10-Q 2026-11-05
Q2 2026
2026-06-30
$33.7M-$62.3M-$60.9M$8.2M$96.7M$116.9M10-Q 2026-08-13
Q1 2026
2026-03-31
$22.7M-$60.6M-$44.9M$24.3M$96.5M$99.0M10-Q 2026-05-15
Q4 2025
2025-12-31
$28.1M-$41.3M-$43.5M$41.3M$96.4M$84.3M10-K 2026-03-09
Q3 2025
2025-09-30
$32.5M-$51.2M-$47.0M$59.6M$96.2M$142.8M10-Q 2026-11-05
Q2 2025
2025-06-30
$15.7M-$44.9M-$39.6M$51.5MNo debt tags$112.3M10-Q 2026-08-13
Q1 2025
2025-03-31
$8.0M-$33.9M-$40.7M$39.9MNo debt tags$97.1M10-Q 2026-05-15
Q4 2024
2024-12-31
$86.6M$49.9M$42.0M$50.8M$0$89.1M10-K 2026-03-09

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2025-01-31
Latest annual report10-K2026-03-09
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-05
Latest proxyDEFA14A2026-04-29

Source: SEC EDGAR submissions feed, 550 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+39.4%
1 month-4.0%
3 months-36.2%
Year to date-66.6%
1 year-53.7%
From 52-week high-70.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ASPEAspen Neuroscience Inc.$12.23-2.86%$355.6M
RZLTRezolute Inc. Common Stock (NV)$3.58-2.05%$346.3M
PBYIPuma Biotechnology Inc$7.34-5.53%$379.5M
CTNMContineum Therapeutics Inc.$9.67-1.93%$379.7M
CRMDCorMedix Inc.$4.82+3.43%$383.4M
RLMDRelmada Therapeutics Inc.$3.61-14.25%$385.2M
IRDOpus Genetics Inc.$4.04+1.51%$390.5M
AVIRAtea Pharmaceuticals Inc.$4.12-4.19%$330.9M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier